Skip to main content.

Jun Zhang, MD, PhD

Professional Background

Jun Zhang, MD, PhD is a physician-scientist, principle investigator, and board certified internist and medical oncologist. Dr. Zhang received his medical degree from the prestigious Xiang-Ya School of Medicine Central South University in China, PhD of Cancer Biology from LSU, postdoctoral fellowship at Harvard Medical School and UCSF, and Hematology/Oncology fellowship at Emory University School of Medicine. Dr. Zhang is passionate in frontier scientific discoveries, and has ample expertise in bench-to-bedside translation and development of investigator initiated clinical trials. He has more than 100 publications including those appeared in high impact journals such as Oncogene, Cancer Research, Clinical Cancer Research, Journal of Thoracic Oncology, Molecular Cancer, Annals of Oncology and Cancer Cell, etc. Dr. Zhang is a member of multiple prestigious organizations including AACR, ASCO, ESMO, IASLC and CAHON where he also served as the Committee Co-chair of Clinical Research.

His research interests include the following broad aspects:
1) The role of microbiota in the oncogenesis, immune modulation and immunotherapy of lung cancer
2) Resistant mechanisms in targeted therapies for non-small cell lung cancer harboring driver mutations
3) Development of innovative interventional and translational trials for various thoracic malignancies.

He is a vital member in leading a multidisciplinary teamwork in both the research and patient care for Thoracic Oncology in KUCC.

Education and Training
  • MD, Clinical Medicine, Hunan Medical University (present: Xiangya School of Medicine, Central South University), Changsha, Hunan
  • PhD, Cellular Biology & Anatomy, Louisiana State University Health Science Center, LA
  • Residency, Internal Medicine, Pulmonology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
  • Post Doctoral Fellowship, Louisiana State University Health Science Center, LA
  • Post Doctoral Fellowship, Dana-Farber Cancer Institute, Harvard Medical School, LA
  • Post Doctoral Fellowship, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA
  • Residency, Internal Medicine, Kingsbrook Jewish Medical Center, Brooklyn, NY
  • Clinical Fellowship, Hematology/Oncology, Winship Cancer Institute Emory, University School of Medicine, Atlanta, GA
Licensure, Accreditations & Certifications
  • Internal Medicine , American Board of Internal Medicine
  • Iowa
  • Kansas
  • Medical Oncology, American Board of Internal Medicine- Medical Oncology
Professional Affiliations
  • European Society for Medical Oncology, Member, 2020 - Present
  • Chinese American Hematologist and Oncologist Network, Member, 2019 - Present
  • Chinese Society of Clinical Oncology, Member, 2018 - Present
  • International Association for the Study of Lung Cancer, Member, 2016 - Present
  • American Society of Clinical Oncology, Member, 2012 - Present
  • American College of Physician, Member, 2009 - Present
  • American Association for Cancer Research, Member, 2001 - Present

Current Research and Grants
  • A Multi-Center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatexo-1), Exelixis and Genentech/Roch: Investigator- Initiated Study, PI
  • A Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed On Or After Treated With Platinum-Based Chemotherapy With/Without Immune Checkpoint Inhibitors (PYRAMID-1; NCT04447118), Hengrui Therapeutics, PI
  • A Randomized, Open-Label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects with Resectable Non-Small Cell Lung Cancer (CANOPY-N; NCT03968419), Novartis Therapeutics, PI
  • Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. 2022. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. The New England Journal of Medicine 2022 Jul 14, 387 (2), 120-131.
  • Roller JF, Veeramachaneni NK, Zhang J. 2022. Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC. Cancers (Basel) 2022 Jan 31, 14 (3), 741.
  • Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, Gupta A, Mercer KN, Eastman E, Abu-Hejleh T, Chan C, Weiner G, Cherwin C, Lee ST, Zhong C, Mangalam A, Zhang J. 2021. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immuotherapy in lung cancer. BMC Cancer 2021 Jul 13, 21 (1), 808.
  • Huang C, Li M, Liu B, Zhu H, Dia Q, Fan X, Mehta K, Huang C, Neupane P, Wang F, Sun W, Umar S, Zhong C, Zhang J. 2021. Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. Frontiers in Oncology 2021 Mar 18, 11, 642110.
  • Bi J, Yang S, Li L, Dai Q, Borcherding N, Wagner BA, Buettner GR, Spitz DR, Leslie KK, Zhang J#, Meng X. 2019. Metadherin enhances vulnerability of cancer cells to ferroptosis. Cell Death & Disease 2019 Sep 17, 10 (10), 682 #Co-corresponding Author .
  • Xu K, Park D, Magis AT, Zhang J, Zhou W, Sica GL, Ramalingam SS, Curran WJ, Deng X. 2019. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. Molecular Cancer 2019 April 10, 18 (1), 85.
  • Strouse C, Mangalam A, Zhang J. 2019. Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. Gut Microbes 2019, 10 (2), 109-112 .
  • Li R, Ding C, Zhang J#, Xie M, Park D, Ding Y, Chen G, Zhang G, Gilbert-Ross M, Zhou W, Marcus AI, Sun SY, Chen ZG, Sica GL, Ramalingam SS, Magis AT, Fu H, Khuri FR, Curran WJ, Owonikoko TK, Shin DM, Zhou J, Deng X. 2017. Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Research 2017 Jun 1, 77 (11), 3001-3012. #Co-1st author .
  • Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. 2017. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 2017 April 10, 31 (4), 487-500.e8.
  • Zhang J, Shridhar R, Dai Q, Song J, Barlow SC, Yin L, Sloane BF, Miller FR, Meschonat C, Li BD, Abreo F, Keppler D. 2004. Cystatin M: a novel candidate tumor suppressor gene for breast cancer. Cancer Research 2004 Oct 1, 64 (19), 6957-64.